Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions

References

• Balimane PV, Han YH, Chong S. (2006). Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8:E1–13.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH. (2004). Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64:5804–5811.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH. (2007). The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71:240–249.
   PubMed Web of Science ®Google Scholar
• Elsby R, Surry DD, Smith VN, Gray AJ. (2008). Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140–1164.
   PubMed Web of Science ®Google Scholar
• Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD. (2011). The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos 39:275–282.
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. (2007). Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229–235.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2010). Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf. Accessed on 8 February 2011.
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, Krajcsi P. (2008). Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 4:721–732.
   PubMed Web of Science ®Google Scholar
• Gupta A, Unadkat JD, Mao Q. (2007). Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 96:3226–3235.
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB. (2006). A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 11:176–183.
   PubMed Web of Science ®Google Scholar
• Huang L, Wang Y, Grimm S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738–742.
   PubMed Web of Science ®Google Scholar
• Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB. (2010). High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos 38:705–714.
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. (2002). Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943–2950.
   PubMed Web of Science ®Google Scholar
• Lechner C, Reichel V, Moenning U, Reichel A, Fricker G. (2010). Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. Eur J Pharm Biopharm 75:284–290.
   PubMed Web of Science ®Google Scholar
• Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K. (2008). Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatol Res 38:300–309.
   PubMed Web of Science ®Google Scholar
• Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. (2009). Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816–1831.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. (2005). Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–1067.
   PubMed Web of Science ®Google Scholar
• Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. (2008). Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51:3275–3287.
   PubMed Web of Science ®Google Scholar
• Poguntke M, Hazai E, Fromm MF, Zolk O. (2010). Drug transport by breast cancer resistance protein. Expert Opin Drug Metab Toxicol 6:1363–1384.
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. (2009). ABCG2: a perspective. Adv Drug Deliv Rev 61:3–13.
   PubMed Web of Science ®Google Scholar
• Shah VP. (2007). The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. AAPS J 9:E43–E47.
   Web of Science ®Google Scholar
• Sharma P, Holmes VE, Elsby R, Lambert C, Surry D. (2010). Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica 40:24–37.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. (2004). Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146–151.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. (2003). ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644–22649.
   PubMed Web of Science ®Google Scholar
• Telbisz A, Müller M, Ozvegy-Laczka C, Homolya L, Szente L, Váradi A, Sarkadi B. (2007). Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta 1768:2698–2713.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. (2006). Draft guidance for industry: Drug interaction studies− study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed 8 February 2011.
   Google Scholar
• Vasiliou V, Vasiliou K, Nebert DW. (2009). Human ATP-binding cassette (ABC) transporter family. Hum Genomics 3:281–290.
   PubMedGoogle Scholar
• Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de Morais S, Duignan DB. (2006). A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3:45–54.
   PubMed Web of Science ®Google Scholar
• Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P. (2003). Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 278:23538–23544.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q. (2005). BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22:2023–2034.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981–2039.
   PubMed Web of Science ®Google Scholar